Mytos, a London, UK-based automated cell manufacturing company, raised $19M in Series A funding.
The round was led by Buckley Ventures, with participation from IQ Capital and Wing VC.
The company intends to use the funds to accelerate the manufacturing and distribution of its automated cell production system to more biotech and pharma companies to meet growing demand.
Led by Ali Afshar, Ph.D, CEO and Ignacio Willats, Mytos specializes in automating cell manufacture. Its platform enables life sciences companies to grow human cells with precision and efficiency. Mytos has assembled a team of engineers and scientists to develop an automated platform to accelerate the development of life-saving therapies. Beginning with stem cells (iPSCs), the system can efficiently manufacture heart cells that spontaneously start beating after 12 days. By automating the entire cell manufacturing process, It ensures cell production and yield, while allowing remote monitoring of cell quality via digital data capture accessible on a smartphone or digital device.
The company’s platform is already in use by a number of life sciences companies globally.
FinSMEs
30/11/2023